All In Biotech

Drug Trial Radar · NCT07047521

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

A Randomized, Double-Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) Versus the Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in a Non-Endemic Area for Dengue

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 496 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

496

Actual

Start

Nov 7, 2025

Primary completion

Jun 29, 2026

Study completion Dec 22, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The TDV in current formulation has been approved by health authorities in many countries around the world. The main aim of the study is to confirm that the TDV new formulation induces the similar immune response as approved TDV. Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. Blood samples will be taken before and after the vaccinations. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 5 times.

Conditions

  • Dengue Fever

Interventions

  • Tetravalent Dengue Vaccine (TDV)Biological

    TDV subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers (GMTs) of Neutralizing Antibodies (By MNT) Against Each of the 4 Dengue Serotypes at Day 120 In the TDV (New) And TDV (Current) GroupsTime frame: At Day 120

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Paratus Clinical Research Western Sydney

    Blacktown, New South Wales, Australia

  • Emeritus Research Sydney

    Botany, New South Wales, Australia

  • Paratus Clinical Research Central Coast

    Kanwal, New South Wales, Australia

  • Veritus Research

    Bayswater, Victoria, Australia

  • Emeritus Research Camberwell (Melbourne)

    Camberwell, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.